Stock Events

Stock Events

Karyopharm Therapeutics 

$9.25
62
-$0.16-1.7% Today

Statistics

Day High
9.61
Day Low
9.18
52W High
10.09
52W Low
3.77
Volume
3,009,036
Avg. Volume
-
Mkt Cap
169.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
Next
-5.71
-4.22
-2.73
-1.24
Expected EPS
-1.244286
Actual EPS
N/A

Financials

-134.21%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
292.13MRevenue
-392.08MNet Income

Analyst Ratings

18Average Price Target
The highest estimate is 28.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KPTI. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Karyopharm's focus on cancer therapeutics.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a strong presence in the oncology and hematology market, directly competing with Karyopharm's cancer drug offerings.
AMGEN
AMGN
Mkt Cap178B
Amgen has a diverse range of cancer drugs that compete with Karyopharm's therapies in multiple myeloma and other cancers.
Merck
MRK
Mkt Cap277.02B
Merck & Co. is a leading pharmaceutical company with a strong lineup of cancer drugs that compete with Karyopharm's products.
Pfizer
PFE
Mkt Cap149.77B
Pfizer has a broad oncology portfolio, including treatments for conditions that Karyopharm's drugs target.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie competes in the oncology market with a focus on cancer treatments, including therapies that could be in direct competition with Karyopharm's products.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca has a significant presence in the oncology sector, with drugs that compete against Karyopharm's offerings in cancer treatment.
Novartis
NVS
Mkt Cap279.67B
Novartis offers a wide range of cancer treatments, including therapies that directly compete with Karyopharm's products.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical division Janssen, has a portfolio of cancer drugs that compete with Karyopharm's therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals, though more focused on biotechnology, has been expanding its oncology portfolio, potentially competing with Karyopharm's cancer treatments.

About

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Show more...
CEO
Mr. Richard A. Paulson M.B.A.
Employees
279
Country
United States
ISIN
US48576U2050

Listings

F
DE
25K0.F
STU
DE
25K0.STU
MU
DE
25K0.MU
BOATS
BOATS
KPTI.BOATS

0 Comments

Share your thoughts

FAQ

What is Karyopharm Therapeutics stock price today?▼
The current price of KPTI is $9.25 USD — it has decreased by -1.7% in the past 24 hours. Watch Karyopharm Therapeutics stock price performance more closely on the chart.
What is Karyopharm Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Karyopharm Therapeutics stocks are traded under the ticker KPTI.
Is Karyopharm Therapeutics stock price growing?▼
KPTI stock has risen by +9.76% compared to the previous week, the month change is a +45.89% rise, over the last year Karyopharm Therapeutics has showed a +47.05% increase.
What is Karyopharm Therapeutics market cap?▼
Today Karyopharm Therapeutics has the market capitalization of 169.68M
When is the next Karyopharm Therapeutics earnings date?▼
Karyopharm Therapeutics is going to release the next earnings report on July 30, 2026.
What is Karyopharm Therapeutics revenue for the last year?▼
Karyopharm Therapeutics revenue for the last year amounts to 292.13M USD.
What is Karyopharm Therapeutics net income for the last year?▼
KPTI net income for the last year is -392.08M USD.
How many employees does Karyopharm Therapeutics have?▼
As of May 06, 2026, the company has 279 employees.
In which sector is Karyopharm Therapeutics located?▼
Karyopharm Therapeutics operates in the Health & Wellness sector.
When did Karyopharm Therapeutics complete a stock split?▼
The last stock split for Karyopharm Therapeutics was on February 26, 2025 with a ratio of 1:15.
Where is Karyopharm Therapeutics headquartered?▼
Karyopharm Therapeutics is headquartered in Newton, United States.